Onconetix, Inc. 8-K

What Happened On April 30, 2026, Onconetix, Inc. held a special meeting of stockholders and approved an amendment to its Certificate of Incorporation to permit one or more reverse stock splits of the company’s common stock at a ratio between 1-for-2 and 1-for-10. The Board may implement a reverse split at any time before the one-year anniversary of the special meeting and may choose the exact ratio within that range without further stockholder approval, provided aggregate reverse splits do not exceed 1-for-100. The company filed the related Form 8-K on May 4, 2026.

Key Details

• Record date and shares: 3,464,686 shares of common stock outstanding as of the March 13, 2026 record date.
• Reverse Stock Split vote: 1,301,918 votes for; 253,378 against; 1,393 abstentions.
• Adjournment proposal vote (to allow additional proxy solicitation if needed): 1,332,088 votes for; 223,071 against; 1,530 abstentions.
• Board authority/timeframe: Board can select a split ratio between 1-for-2 and 1-for-10 and implement within one year; cumulative effect of splits cannot exceed 1-for-100.

Why It Matters A reverse stock split, if implemented, will reduce the number of outstanding shares and proportionally increase the per-share price, which can affect trading liquidity, per-share metrics, and share counts reported to investors. Stockholders authorized the change and gave the Board flexibility to choose timing and ratio, but no reverse split has been implemented yet — the approval only permits the Board to act within the next year.